N/A
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) just released its latest quarterly results and things are looking bullish...
After the close today, Puma issued a news release detailing results for the first quarter of 2026. Today's conference call will include statements about Puma's future expectations, plans and prospects that constitute forward-looking statements for purposes of federal securities laws.
Puma Biotechnology (NASDAQ:PBYI) reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company’s earnings call. Management attributed the quarter’s product revenue
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Moby summary of Puma Biotechnology, Inc.'s Q1 2026 earnings call